Skip to main content

SYSTEMATIC REVIEW article

Front. Gastroenterol.
Sec. Hepatology
Volume 4 - 2025 | doi: 10.3389/fgstr.2025.1511150
This article is part of the Research Topic World Hepatitis Day - Advances in Hepatitis Research: Bridging Gaps and Exploring New Frontiers View all articles

Real-world effectiveness of Sofosbuvir/Velpatasvir, Glecaprevir/Pibrentasvir, and Sofosbuvir/Velpatasvir/Voxilaprevir against genotype 3 HCV infection: a systematic review and meta-analysis

Provisionally accepted
Liwei Zhuang Liwei Zhuang *Junnan Li Junnan Li Yu Zhang Yu Zhang Shibo Ji Shibo Ji Huichun Xing Huichun Xing
  • Beijing Ditan Hospital, Capital Medical University, Beijing, China

The final, formatted version of the article will be published soon.

    Introduction: Direct antiviral agents (DAAs) have dramatically changed the landscape of liver diseases associated with chronic hepatitis C virus (HCV) infection. However, limited data are available on the antiviral effect of sofosbuvir (SOF) + velpatasvir (VEL) ± ribavirin (RBV), SOF + VEL + voxilaprevir (VOX) and glecaprevir (GLE) + pibrentasvir (PIB) in treating patients infected with HCV GT3 in a real-world setting. Methods: Using EMBASE, PubMed, and Cochrane Library databases, articles were screened from January 1, 2016, to June 1, 2024. The sustained virologic response (SVR) rates were analyzed using R4.1.0 software by the Freeman-Tukey double arcsine transformation in a random-effects model.We recruited 3177 patients with HCV GT3 in 19 studies from 9 countries. The pooled SVR12/24 rate of the three evaluated regimens was 94.00% (95% CI: 90.87-96.59%). Also, the SVR rates were 83.81% (95% CI: 75.70-2 90.62%) in patients receiving SOF+VEL+VOX; 94.98% (95% CI: 92.02-97.33%) in patients receiving SOF+VEL±RBV; and 96.96% (95% CI: 93.20-99.45%) in patients receiving GLE+PIB. The pooled SVR12/24 rates of the three regimens were 95.70% (95% CI: 91.74-98.58%) and 90.50% (95% CI: 83.50-95.90%) in non-cirrhotic and cirrhotic patients, respectively. The pooled SVR rates were 96.79% (95% CI: 93.37-99.13%) and 88.41% (95% CI: 82.67-93.22%) in treatment-naive and treatment-experienced patients, respectively. Conclusion: SOF+VEL±RBV, GLE+PIB, and SOF+VEL+VOX had good antiviral effectiveness for chronic HCV-GT3 infection in real-world settings.Factors such as cirrhosis and treatment experience, especially previous DAA treatment failure, may influence the SVR rate.

    Keywords: real-world effectiveness, Sofosbuvir/velpatasvir, Glecaprevir/pibrentasvir, sofosbuvir/velpatasvir/voxilaprevir, Genotype 3 HCV

    Received: 14 Oct 2024; Accepted: 08 Jan 2025.

    Copyright: © 2025 Zhuang, Li, Zhang, Ji and Xing. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Liwei Zhuang, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.